TrialThe lancet. HIV2021

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.

Shabir A Madhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.